Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03612284 · ClinicalTrials.gov registry record · NA
Scleral Contact Lens Insertion Solution Study
A NA study, sponsored by Jennifer Fogt.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03612284: Completed NA study, sponsored by Jennifer Fogt.
NCT03612284 is a NA study that has completed, run by Jennifer Fogt. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03612284, a NA study, has completed, sponsored by Jennifer Fogt.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical ocular compatibility (feasibility of safety and efficacy) of a patented solution (US Patent 2,259,437, Stone) which contains multiple essential ions and has a pH and tonicity which more closely mimics human tears as compared to the subjects' current habitual scleral lens insertion solution.
Primary Outcome
ocular safety examination
Interventions
- DEVICE contact lens insertion solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2018-11-30 |
| Phase | NA |
What the finished NCT03612284 record still lists
NCT03612284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which contact lens insertion solution is the first listed.
NCT03612284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03612284 about?
NCT03612284 is a clinical study titled "Scleral Contact Lens Insertion Solution Study". The purpose of this study is to determine the clinical ocular compatibility (feasibility of safety and efficacy) of a patented solution (US Patent 2,259,437, Stone) which contains multiple essential ions and has a pH and tonicity which more closely mimics human tears as compared to the subjects' cur...
What is the current status of trial NCT03612284?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-11-27. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03612284?
The interventions under investigation include: contact lens insertion solution (DEVICE).
Who is sponsoring clinical trial NCT03612284?
This trial is sponsored by Jennifer Fogt, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03612284's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI